Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume 24, Issue 7, Pages 1319-1322Publisher
WILEY
DOI: 10.1002/ejhf.2590
Keywords
SARS-CoV-2 vaccine; Giant cell myocarditis; Cardiac magnetic resonance imaging; Endomyocardial biopsy
Categories
Funding
- Projekt DEAL
Ask authors/readers for more resources
This case report describes a young man who was admitted to the Department of Cardiology and Angiology at Hannover Medical School with symptoms of shortness of breath and elevated troponin. After being diagnosed with giant cell myocarditis and having received the first dose of BioNTech's mRNA vaccine, the patient was treated with immunosuppressive therapy. The article discusses this rare etiology of myocarditis following mRNA vaccination and the treatment strategy employed in this particular case according to current recommendations.
Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work-up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context of myocarditis after mRNA vaccination we discuss this rare aetiology and the patient's treatment strategy in the light of current recommendations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available